Radisens is a market-led medical diagnostics company with a mission to become the #1 diagnostics solution provider at point-of-care [PoC]. Our aim is to fulfill the unmet market need for a connected sample-to-answer blood analyzer with an integrated test menu across full chronic disease pathways. Performance from our market-leading, patented technology has generated significant partnership engagements with the leading global diagnostic companies.
No solution on the market offers an affordable quantitative diagnostic platform supporting the rapid diagnosis of multiple high-sensitivity immunoassays, clinical chemistries and haematology (cell counting) assays at point-of-care….
Radisens is targeting the $6bn PoC in-vitro diagnostic market within physician’s office, outpatient departments and community clinics. Healthcare systems worldwide struggle to cope with the increasing global chronic disease epidemic (diabetes, obesity, heart disease, renal disease, thyroid disorders, …), the relentless drive for cost savings and need to better manage long-term chronic disease.
Studies show that regular patient monitoring at PoC reduces chronic disease risk factors, improving near term patient outcomes, and reducing long term chronic complications. Healthcare providers worldwide are increasingly focused on such preventative healthcare programmes as the solution to better patient outcomes and lower long term costs. However, there is no enabling PoC device with central laboratory-grade performance that can offer physicians multipexed test panels for full chronic disease pathways…. until now.
Existing devices typically offer single-parameter blood test results that tend to be qualitiative. This results in physicians requiring myriad of bespoke diagnostic test devices to offer patients a minimal test menu at PoC, but not to central laboratory-grade performance. With initial chronic disease panels across diabetes, thyroid function, kidney disease, heart disease and cell counting tests, Radisens fill these market need, to demonstrated central lab-grade performance. Radisens’ roadmap extends to cardiac, oncology and metabolic panels.
